Sanofi India Limited Holds 70th AGM, Approves Financials & Dividends
Sanofi India Limited held its 70th AGM on April 29, 2026. Shareholders approved the annual audited financial statements for FY 2025 and a final dividend of ₹48 per share, in addition to an interim dividend of ₹75 per share. Key appointments and related party transactions were also approved.
The approval of dividends and board appointments are material events for shareholders and the company's governance structure.
The AGM successfully concluded with the approval of financial statements, dividends, and key appointments, indicating a positive and smooth governance process.
Sanofi India Limited convened its 70th Annual General Meeting (AGM) on Wednesday, 29th April 2026, conducted virtually via Video Conferencing / Other Audio Visual Means. The meeting commenced at 3:30 p.m. IST, with 72 members attending.
The AGM focused on approving key resolutions, including the adoption of the Annual Audited Financial Statements for the financial year ended 31st December 2025, which encompass the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement, along with the Board of Directors' and Auditors' reports. Shareholders also approved the payment of an interim dividend of ₹75 per equity share and a final dividend of ₹48 per equity share for the financial year ended 31st December 2025. The re-appointment of Mr. Vaibhav Karandikar and Mr. Eric Mansion, who retired by rotation, was also confirmed.
Significant corporate actions approved included the appointment of Ms. Sudipta Chakraborty as a Director and Whole-time Director, and the appointment of Ms. Rajani Kesari and Mr. Siraj Azmat Chaudhry as Independent Directors for a term of five years from 1st April 2026 to 31st March 2031. Additionally, resolutions were passed to approve material related party transactions with Sanofi-Aventis Singapore Pte. Limited and Sanofi Healthcare India Private Limited. The remuneration payable to the Cost Auditors for the financial year ending 31st December 2026 was also ratified.
The meeting saw presentations on the company's operational and financial performance for FY 2025 by Managing Director Mr. Deepak Arora, followed by a discussion on future outlook. The proceedings also included the formal conclusion of the tenure of Independent Director Mrs. Usha Thorat and the handover of the Chairman position from the outgoing Chairman to Mr. Rahul Bhatnagar, effective 30th April 2026.
The AGM concluded at 5:25 p.m. IST, with the consolidated voting results to be declared within the stipulated timeline.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.